Skip to content
Head to head

Viatris vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: VTRS · TAK

Updated 6 minutes ago

1-year performance, rebased to 100

VTRS +90.6%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical earns the most per share.
VTRSTAK
Snapshot
Sector----
Last price19.6321.77
Change today-1.26%+1.68%
1-year return+99.3%+57.5%
Market cap$22.50B$69.76B
52-week range10.15 – 21.2013.92 – 22.07
Valuation
P/E (TTM)-37.04311.00
P/E percentile, own 5-yr range16th100th
P/B1.641.50
Dividend yield2.45%1.44%
Profitability & growth
EPS (TTM)-3.00-0.30
Net profit (TTM)$-3.44B$-970.94M
Revenue (TTM)$14.73B$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-0.3%+6.7%
Gross margin35.3%65.8%
Operating margin1.0%14.3%
Net margin-4.1%0.9%
Free cash flow (TTM)$1.98B$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership91.8%51.3%
Insider activity (12mo)40 buy / 10 sell19 buy / 31 sell
Short interest (% of float)3.1%0.1%
Analyst consensus62% buy / 25% hold / 12% sell (8)100% buy (1)
Analyst price target$23 (+15%)$50 (+132%)
StockVane view
StockVane Quant RatingC (97)C (90)
Company
Employees30,00047,029
Founded20191781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.